Orient Securities(600958)
Search documents
研报掘金丨东方证券:维持长信科技“买入”评级,目标价6.44元
Ge Long Hui A P P· 2025-12-03 06:20
Core Viewpoint - Changxin Technology has a broad customer base in the automotive electronics sector, covering over 70% of global vehicle brands, and has established a comprehensive supply chain for integrated modules [1] Group 1: Business Overview - The company provides a range of automotive electronic modules, including instrument panel modules, rearview mirror modules, central control screen modules, B-pillar modules, and head-up display modules [1] - Changxin Technology has completed the industrial chain layout for "on-board sensors + touch modules + cover plates + touch display integrated modules" [1] Group 2: Growth Potential - The company is expanding into fields such as UTG and UFG, which are expected to open up new growth opportunities [1] - Additionally, the company is entering the intelligent computing sector, aiming to build a full-chain computing service capability [1] Group 3: Valuation - Based on comparable companies' average 26-year PE valuation of 28 times, the target price is set at RMB 6.44, maintaining a "buy" rating [1]
申能集团携旗下东方证券捐赠500万港元,支援香港火灾救援
Di Yi Cai Jing· 2025-12-03 05:46
公司将密切关注后续救灾情况,为受灾民众提供必要支持,助力其重建家园、恢复正常生活,积极履行 企业社会责任,彰显国有金融企业使命担当和人文关怀。 东方证券作为A+H股上市公司,在港提供全链条金融服务体系,与香港社会联系紧密、共生共荣。公 司对于香港火灾中的遇难同胞表示深切哀悼,向不畏艰险、奋战一线的救援人员致以崇高敬意,时刻心 系当地居民生命财产安全。 近日,申能集团携旗下东方证券(含汇添富基金)及其香港公司捐赠500万港元,通过香港白玉兰基金 会,驰援香港大埔火灾救助工作,专项用于香港大埔火灾受灾民众的救助与灾后重建工作。 ...
“千钧奋起,万树花开”年度策略会圆满召开
Qi Huo Ri Bao Wang· 2025-12-03 02:36
2025年11月28日,由东证期货与东方证券财富管理委员会联合主办"千钧奋起,万树花开"年度策略会在 上海浦东顺利召开,本次会议设置1个主论坛与4个分论坛,议程覆盖宏观经济与政策、大宗商品、产业 动态及大类资产配置等多个领域,为500余名各界投资者搭建了专业高效的交流平台。 东证期货党委副书记、总经理唐雷出席本次策略会并发表致辞。他表示,2025年宏观图景的核心脉络聚 焦"破"与"立",期货行业已正式从"量的扩张"阶段迈入"质的突围"的全新发展阶段。当前,期货行业既 迎来了新的发展高度,也处于转型关键节点。面对行业变局与多重挑战,东证期货明确两大核心发力方 向:一是坚持研究下沉,扎实推进产业链深度研究,这份源自一线实践的"泥土气息",正是公司稳健发 展的最坚实底气;二是深化科技赋能,推动金融科技从辅助工具升级为核心竞争力,将大数据平台"繁 微"打造为连接研究、决策与风险管理的智慧中枢,凭借技术优势突破传统业务瓶颈,为客户创造独特 价值。 策略会主论坛特别邀请复旦大学经济学院副院长陈钊教授,带来"在变化中把握机遇:创新、市场与 AI"的主题分享。陈钊教授指出,坚持创新发展是中国崛起的重要道路。企业必须具备国际视 ...
东方证券(600958) - 东方证券:H股公告(截至2025年11月30日止之股份发行人的证券变动月报表)

2025-12-02 09:30
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 東方證券股份有限公司 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | A | | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 600958 | 說明 | 上海證券交易所 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 7,469,482,864 | RMB | | | 1 RMB | | 7,469,482,864 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 7,469,482,864 | RMB | | | 1 RMB | | 7,469,482,864 | | ...
东方证券(03958) - 截至二零二五年十一月三十日止月份之股份发行人的证券变动月报表

2025-12-02 08:52
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 | 2. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03958 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,027,162,428 | RMB | | 1 RMB | | 1,027,162,428 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 1,027,162,428 | RMB | | 1 RMB | | 1,027,162,428 | 本月底法定/註冊股本總額: RMB 8,496,645,292 FF301 第 1 頁 共 10 頁 v 1.1.1 致:香港交易及結算所有限公司 公司名稱: 東方證券股份有 ...
每日互动连亏2年连3季 A股募5.2亿IPO东方证券保荐
Zhong Guo Jing Ji Wang· 2025-12-02 07:59
每日互动首次公开发行股票的发行费用总额为7,438.26万元,其中承销及保荐费为4,507.26万元。 每日互动于2024年12月26日披露2024年度向特定对象发行A股股票预案。该公司本次向特定对象发 行股票募集资金总额不超过78,067.85万元(含本数),扣除发行费用后拟投资于可控智算能力平台建设 与行业垂直模型产业化项目、公共与产业数据价值开发平台(发数站)项目和补充流动资金。 | | 2024 年 | 2023 年 | 本年比上年增减 | 2022 年 | | --- | --- | --- | --- | --- | | 营业收入(元) | 470, 363, 638. 37 | 429, 913, 361. 35 | 9.41% | 525, 895, 442. 02 | | 归属于上市公司股东的净利润(元) | -64,755,232.21 | -49,931,430.41 | -29.69% | 26, 286, 896. 02 | | 归属于上市公司股东的扣除非经常性 损益的净利润(元) | 19,525,048.06 | -25, 122, 212. 88 | 177.72% | 20, ...
研报掘金丨东方证券:维持罗莱生活“增持”评级,看好公司未来业绩增长持续性
Ge Long Hui A P P· 2025-12-02 07:04
Core Viewpoint - The report from Dongfang Securities highlights the significant effectiveness of the explosive product strategy and expresses optimism about the sustainability of Luolai Life's future performance growth [1] Group 1: Product Strategy and Performance - Luolai Life has been actively exploring product and model innovations, launching the "Zero Pressure Deep Sleep Pillow" for the 2024 Double Eleven and the "Seamless Sleep Bed Cover" for 2025, amidst a generally weak consumer environment [1] - The explosive product strategy has shown remarkable results, with revenue and profit growth of 9.9% and 50% respectively in Q3 of this year [1] - The company's main brand ranked among the top during the previous Double Eleven event, establishing a solid foundation for Q4 performance [1] Group 2: Market Impact and Investment Value - The explosive products not only drive their own sales but also effectively expand the customer base and boost sales of other products [1] - The company has consistently maintained high cash dividends, which are expected to continue, further enhancing its investment value [1] - Based on comparable companies, a 15x PE valuation for 2026 is suggested, corresponding to a target price of 11.34 yuan, with a maintained "Buy" rating [1]
东方证券某营业部收警示函 个别电脑未纳入监控系统等
Zhong Guo Jing Ji Wang· 2025-12-02 06:43
中国经济网北京12月2日讯 中国证监会辽宁监管局网站近日发布关于对东方证券股份有限公司沈阳 南八中路证券营业部采取出具警示函措施的决定。 经查,该营业部存在以下问题:一是营销活动方案未见审核程序及合规审查记录。二是个别电脑未 纳入监控系统。三是证券经纪人薪酬分配仅与客户交易量挂钩,证券经纪业务从业人员绩效考核和薪酬 分配机制不完善。四是未保留金融产品推介服务相关资料。 上述行为违反了《证券公司和证券投资基金管理公司合规管理办法》(证监会令第166号)第三 条、第六条第四项、《证券经纪业务管理办法》(证监会令第204号)第三十八条、《证券公司代销金 融产品管理规定》(证监会公告〔2020〕20号)第十六条的规定。 根据《证券公司和证券投资基金管理公司合规管理办法》(证监会令第166号)第三十二条第一 款、《证券经纪业务管理办法》(证监会令第204号)第四十三条、《证券公司代销金融产品管理规 定》(证监会公告〔2020〕20号)第二十条的规定,辽宁证监局决定对东方证券股份有限公司沈阳南八 中路证券营业部采取出具警示函的监管措施。 (责任编辑:田云绯) ...
东方证券:智能眼镜发售节奏加快提速 眼镜配套企业有望受益
智通财经网· 2025-12-01 08:59
Core Insights - Alibaba's Quark AI glasses were officially launched on November 27, featuring a unique design with ultra-thin temples and frames, with the temples measuring only 7.5mm, the narrowest in the global market for similar products [1][2] - The Quark glasses come in two series: S1 (with display) starting at 3799 yuan and G1 (without display) starting at 1899 yuan, showcasing advanced technology including dual flagship chips and adjustable focal distance [2][3] - The smart glasses market is expected to accelerate, with major brands like Meta and Xiaomi releasing their products, indicating a growing trend towards smart eyewear by 2026 [3][4] Product Features - The Quark AI glasses have four main features: ultra-thin design, a dual battery replacement system, an integrated fitting solution with Conant Optical, and deep integration with Alibaba's ecosystem through the Qianwen AI assistant [2][4] - The S1 model weighs approximately 51 grams and can capture images in 0.6 seconds, while the G1 model weighs around 40 grams, maintaining similar hardware specifications [2] Market Dynamics - The pricing strategy for Quark lenses includes a 13% tax and profit margin, suggesting that Alibaba may not be overpricing its lenses, which could enhance the profitability of fitting companies [4] - The smart glasses market is characterized by the need for customization due to varying consumer prescriptions, making partnerships with eyewear companies essential for reaching end consumers [4] Related Companies - Key players in the eyewear sector include Conant Optical (02276), Doctor Glasses (300622.SZ), and Mingyue Lenses (301101.SZ), among others [5]
华康股份终止收购:去年股价提前涨停 为东方证券项目
Zhong Guo Jing Ji Wang· 2025-12-01 07:12
Core Viewpoint - The Shanghai Stock Exchange has decided to terminate the review of Zhejiang Huakang Pharmaceutical Co., Ltd.'s asset acquisition and related transactions, leading the company to withdraw its application for the issuance of shares and cash payment for the acquisition of Henan Yuxin Sugar Alcohol Co., Ltd. [1][3][4] Group 1: Termination of Transaction - Huakang Pharmaceutical announced the termination of its plan to acquire 100% of Yuxin Sugar Alcohol through a combination of share issuance and cash payment, following discussions with relevant parties [3][4] - The decision to terminate the transaction was made after careful consideration by the company's board, citing significant changes in the market environment since the initial planning of the transaction [4] Group 2: Financial Performance - In 2024, Huakang Pharmaceutical reported a revenue of 2.81 billion, a year-on-year increase of 0.93%, while the net profit attributable to shareholders decreased by 27.72% to 268 million [6][8] - For the first three quarters of 2025, the company achieved a revenue of 2.96 billion, reflecting a year-on-year growth of 40.52%, but the net profit attributable to shareholders decreased by 9.91% to 168 million [6][9] Group 3: Transaction Details - The proposed transaction involved a total price of 1.098 billion, with 732 million to be paid in shares and 366 million in cash, and was assessed to have an estimated value of 1.101 billion for the 100% equity of Yuxin Sugar Alcohol [5][6] - The evaluation indicated a significant increase in value, with an appreciation of 55.6 million, resulting in a growth rate of 102.01% compared to the company's net assets [6]